CN103998609A - 通过递送人工转录因子调节受体表达 - Google Patents

通过递送人工转录因子调节受体表达 Download PDF

Info

Publication number
CN103998609A
CN103998609A CN201280049781.2A CN201280049781A CN103998609A CN 103998609 A CN103998609 A CN 103998609A CN 201280049781 A CN201280049781 A CN 201280049781A CN 103998609 A CN103998609 A CN 103998609A
Authority
CN
China
Prior art keywords
glu
lys
thr
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049781.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.弗拉梅
A.纽茨纳
A.赫克斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ali Verta AG Difficult To Understand
Original Assignee
Ali Verta AG Difficult To Understand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ali Verta AG Difficult To Understand filed Critical Ali Verta AG Difficult To Understand
Publication of CN103998609A publication Critical patent/CN103998609A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201280049781.2A 2011-10-11 2012-10-10 通过递送人工转录因子调节受体表达 Pending CN103998609A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
EP11184706.7 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
CN103998609A true CN103998609A (zh) 2014-08-20

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049781.2A Pending CN103998609A (zh) 2011-10-11 2012-10-10 通过递送人工转录因子调节受体表达

Country Status (21)

Country Link
US (1) US20140296129A1 (https=)
EP (1) EP2766484A2 (https=)
JP (1) JP2014530607A (https=)
KR (1) KR20140079780A (https=)
CN (1) CN103998609A (https=)
AU (1) AU2012323032A1 (https=)
BR (1) BR112014008456A2 (https=)
CA (1) CA2851560A1 (https=)
CL (1) CL2014000897A1 (https=)
CO (1) CO6930308A2 (https=)
EA (1) EA201490531A1 (https=)
HK (1) HK1197083A1 (https=)
IL (1) IL231865A0 (https=)
IN (1) IN2014CN02586A (https=)
MA (1) MA36970A1 (https=)
MX (1) MX2014004331A (https=)
PH (1) PH12014500786A1 (https=)
SG (1) SG11201400701WA (https=)
TN (1) TN2014000117A1 (https=)
WO (1) WO2013053719A2 (https=)
ZA (1) ZA201401960B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304314A (zh) * 2020-02-25 2020-06-19 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035110A1 (en) * 2001-10-24 2003-05-01 Cedars-Sinai Medical Center Treating vascular disease by inhibiting toll-like receptor-4
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
WO2011070049A1 (en) * 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39229E1 (en) * 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ527476A (en) * 2001-02-21 2006-06-30 Novartis Ag Zinc finger binding domains for nucleotide sequence ANN
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
JP2012521766A (ja) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた高親和性ＩｇＥ受容体α鎖（ＦＣεＲ１α）遺伝子発現のＲＮＡ干渉媒介性阻害

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035110A1 (en) * 2001-10-24 2003-05-01 Cedars-Sinai Medical Center Treating vascular disease by inhibiting toll-like receptor-4
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
WO2011070049A1 (en) * 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ERIC VIVÈS 等: "Cell-penetrating and cell-targeting peptides in drug delivery", 《BIOCHIMICA ET BIOPHYSICA ACTA》, 1 December 2008 (2008-12-01), pages 1 - 26 *
HEMING YANG 等: "Molecular characterization of the 5"-flanking region of human genomic ETA gene", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》, vol. 190, no. 2, 29 January 1993 (1993-01-29), pages 332 - 339, XP024768238, DOI: 10.1006/bbrc.1993.1052 *
KYOKO TAKAHASHI 等: "Epigenetic Regulation of TLR4 Gene Expression in Intestinal Epithelial Cells for the Maintenance of Intestinal Homeostasis", 《THE JOURNAL OF IMMUNOLOGY》, vol. 183, no. 10, 21 October 2009 (2009-10-21), pages 6522 - 6529, XP055055551, DOI: 10.4049/jimmunol.0901271 *
KYOKO TAKAHASHI 等: "Transcriptional regulation of the human high affinity IgE receptor α-chain gene", 《MOLECULAR IMMUNOLOGY》, vol. 38, no. 1618, 1 September 2002 (2002-09-01), pages 1193 - 1199, XP055055587, DOI: 10.1016/S0161-5890(02)00062-7 *
S PLANEL 等: "A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1", 《ONCOGENE》, 11 November 2010 (2010-11-11), pages 5989 - 6003, XP055015865, DOI: 10.1038/onc.2010.341 *
SATORU YOKOYAMA 等: "SOX10, in combination with Sp1, regulates the endothelin receptor type B gene in human melanocyte lineage cells", 《FEBS JOURNAL》, vol. 2738, no. 8, 1 April 2006 (2006-04-01), pages 1805 - 1820, XP055054902, DOI: 10.1111/j.1742-4658.2006.05200.x *
SERA 等: "Zinc-finger-based artificial transcription factors and their applications", 《ADVANCED DRUG DELIVERY REVIEWS》, vol. 61, no. 78, 2 July 2009 (2009-07-02), pages 513 - 526, XP026139402, DOI: 10.1016/j.addr.2009.03.012 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304314A (zh) * 2020-02-25 2020-06-19 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用

Also Published As

Publication number Publication date
SG11201400701WA (en) 2014-08-28
EA201490531A1 (ru) 2014-08-29
WO2013053719A2 (en) 2013-04-18
HK1197083A1 (en) 2015-01-02
BR112014008456A2 (pt) 2017-04-11
CL2014000897A1 (es) 2014-11-21
TN2014000117A1 (en) 2015-07-01
KR20140079780A (ko) 2014-06-27
US20140296129A1 (en) 2014-10-02
IL231865A0 (en) 2014-05-28
WO2013053719A3 (en) 2013-06-27
EP2766484A2 (en) 2014-08-20
CO6930308A2 (es) 2014-04-28
MX2014004331A (es) 2014-11-26
CA2851560A1 (en) 2013-04-18
MA36970A1 (fr) 2016-03-31
PH12014500786A1 (en) 2021-08-09
AU2012323032A1 (en) 2014-04-03
ZA201401960B (en) 2015-06-24
IN2014CN02586A (https=) 2015-08-07
JP2014530607A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
CN103998609A (zh) 通过递送人工转录因子调节受体表达
CN108350467B (zh) 基因构建体
DE69934425T2 (de) Thrombopoietin substitute
HUT73100A (en) Regulated apoptosis
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
KR20000069617A (ko) Ｏｂ 융합 단백질 조성물과 그 제조 방법
WO1994023751A1 (de) Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
CA2301157A1 (en) Conjugates that contain the homeodomain of antennapedia
CN108473546A (zh) Mg53突变体及其制备方法和用途
US5705484A (en) Biologically active polypeptide fusion dimers
CN110869386A (zh) 重组神经生长因子的组合物和方法
CN114874333B (zh) 一种生长激素融合蛋白及其应用
JP2016515596A (ja) Ｏｐａ１ハプロ不全に起因する疾患の治療のための人工転写因子
CN102584976A (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
JP2020072716A (ja) 細胞透過組成物およびそれを用いる方法
JP2013523719A (ja) 血管新生促進用ペプチド及びその使用
CA2909044A1 (en) Rhomboid proteins and uses thereof
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
KR19980064258A (ko) 항비만 단백질
WO2007046634A1 (en) Method for preparing recombinant peptide from spider venom and analgesic composition containing the peptide
EP1605964B1 (en) TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
HUT56881A (en) Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus
JPWO2014034922A1 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
JP2006508695A (ja) 単量体インスリン
JP4686780B2 (ja) 細胞死抑制活性強化タンパク質ｆｎｋを用いた脱毛の防止

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197083

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140820

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1197083

Country of ref document: HK